Barclays Remains Bullish on Gilead

Barclays analyst Geoff Meacham remains bullish on drug maker Gilead (GILD) despite its recent disappointing first quarter and management's failure to implement a profitable strategy.

Shares of the Foster City, CA. biopharmaceutical firm are lower by over 10% year-to-date. 

However, Meacham remains bullish on Gilead with a 12-month price target of $85, suggesting a 33% upside for the shares.

"Gilead continues to look for the right deal (vs. just any deal), one that would provide an asset or platform capable of establishing a leadership position," Meacham wrote. "Management noted that it remains focused on the long-term, sustainable option rather than a short-term fix."

Jim Cramer and Real Money columnists discuss the latest from President Donald Trump and the GOP efforts to repeal and replace the Affordable Care Act. See which stocks they are discussing and get his insights or analysis with a free trial subscription to Real Money.

More from Stocks

Why Darden and Kroger Served Up Some Mind-Blowing Earnings Reports

Why Darden and Kroger Served Up Some Mind-Blowing Earnings Reports

Daimler's Profit Warning Should Terrify Traders Before Earnings Season Begins

Daimler's Profit Warning Should Terrify Traders Before Earnings Season Begins

Trade Tussle Sinks Stocks, Oil Slides, Micron, Daimler - 5 Things You Must Know

Trade Tussle Sinks Stocks, Oil Slides, Micron, Daimler - 5 Things You Must Know

Futures Fall on Further Trade Rhetoric from China and 4 Other Stories to Watch

Futures Fall on Further Trade Rhetoric from China and 4 Other Stories to Watch

Chart: Goldman Sachs Doesn't See U.S. Economy Falling Apart Anytime Soon

Chart: Goldman Sachs Doesn't See U.S. Economy Falling Apart Anytime Soon